Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Triple-Negative Breast Cancer: Understanding Wnt Signaling in Drug Resistance Publisher



Merikhian P1 ; Eisavand MR1 ; Farahmand L1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant protein department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, 146, South Gandhi Ave., Vanak Circus, Tehran, Iran

Source: Cancer Cell International Published:2021


Abstract

Triple-negative breast cancer (TNBC) is not as prevalent as hormone receptor or HER2-positive breast cancers and all receptor tests come back negative. More importantly, the heterogeneity and complexity of the TNBC on the molecular and clinical levels have limited the successful development of novel therapeutic strategies and led to intrinsic or developed resistance to chemotherapies and new therapeutic agents. Studies have demonstrated deregulation of Wnt/β-catenin signaling in tumorigenesis which plays decisive roles at the low survival rate of patients and facilitates resistance to currently existing therapies. This review summarizes mechanisms of Wnt/β-catenin signaling for resistance development in TNBC, the complex interaction between Wnt/β-catenin signaling, and the transactivated receptor tyrosine kinase (RTK) signaling pathways, lymphocytic infiltration, epithelial-mesenchymal transition (EMT), and induction of metastasis. Such associations and how these pathways interact in the development and progression of cancer have led to the careful analysis and development of new and effective combination therapies without generating significant toxicity and resistance. © 2021, The Author(s).
Related Docs
View other Related Docs
1. Role of the Wnt and Gtpase Pathways in Breast Cancer Tumorigenesis and Treatment, Cytokine and Growth Factor Reviews (2022)
2. Crosstalk Between Muc1 and Vegf in Angiogenesis and Metastasis: A Review Highlighting Roles of the Muc1 With an Emphasis on Metastatic and Angiogenic Signaling, Cancer Cell International (2021)
3. Muc1 Is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy, Cancer Cell International (2022)
4. Breast Cancer Immunotherapy: Current and Novel Approaches, International Immunopharmacology (2021)
5. Cellular Stress Response to Extremely Low-Frequency Electromagnetic Fields (Elf-Emf): An Explanation for Controversial Effects of Elf-Emf on Apoptosis, Cell Proliferation (2021)
6. Improvement of Cytotoxicity and Necrosis Activity of Ganoderic Acid a Through the Development of Pmbn-A.Her2-Ga As a Targeted Nano System, RSC Advances (2022)
7. Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors, Molecular Oncology (2022)
8. Current Therapeutic Approaches and Promising Perspectives of Using Bioengineered Peptides in Fighting Chemoresistance in Triple-Negative Breast Cancer, Biochemical Pharmacology (2023)
Experts (# of related papers)
Nima Rezaei (1)
Other Related Docs
9. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression, International Immunopharmacology (2023)